ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

ASTH vs V // EV/EBITDA & P/E VALUATION

Astrana Health Inc. (NASDAQ) VS. Visa Inc. (NYSE) • 15-METRIC TALLY: ASTH 3 — V 9
▲ EV/EBITDA & P/E VALUATION LEADER: ASTH
valuation
27.3x
valuation
28.9x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ASTH VS. V) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC ASTH V SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) 4.60% 32.30% -27.70 V /roic <GO>
EV/EBITDA & P/E Valuation ACTIVE 27.3x 28.9x -1.60 ASTH /valuation <GO>
Free Cash Flow Yield 5.75% 2.90% +2.85 ASTH /fcf-yield <GO>
Operating Margin 2.50% 60.00% -57.50 V /operating-margins <GO>
Net Profit Margin 0.80% 50.10% -49.30 V /net-margins <GO>
Revenue Growth (YoY) 56.40% 11.30% +45.10 ASTH /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.43% 0.63% -0.20 V /dividend-safety <GO>
Altman Z-Score & Debt/Equity 2.54 9.09 -6.55 V /balance-sheet <GO>
Piotroski F-Score Quality 6/9 9/9 -3.00 V /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 46.7 65.6 -18.88 V /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — 1.06 — TIE /macro-sensitivity <GO>
Forward P/E Multiple 63.6x 34.0x +29.60 V /forward-pe <GO>
Enterprise Scale & Market Cap $1.82B $733.53B -$731.72B V /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR ASTH REV V REV ASTH GROSS % V GROSS % ASTH FCF V FCF
FY 2025 $3.18B $40.00B — — $104.5M $21.26B
FY 2024 $2.03B $35.93B — — $44.2M $18.33B
FY 2023 $1.39B $32.65B — — $68.2M $19.29B
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ASTH // BETA —
V // BETA 1.06